Beauty Health (NASDAQ:SKIN) Now Covered by Roth Capital

Key Points

• Roth Capital has initiated coverage of Beauty Health (NASDAQ:SKIN) with a "buy" rating and a price target of $3.50, indicating a potential upside of 47.68% from the stock's previous close.
• Beauty Health reported earnings of $0.03 EPS for the quarter, surpassing analysts' expectations of a loss, with revenue of $78.20 million compared to estimates of $74.67 million.
• Several institutional investors have increased their stakes in Beauty Health, with institutional ownership now at 93.26% of the company's stock.

Stock analysts at Roth Capital began coverage on shares of Beauty Health (NASDAQ:SKIN - Get Free Report) in a report released on Friday,Briefing.com Automated Import reports. The brokerage set a "buy" rating and a $3.50 price target on the stock. Roth Capital's price target points to a potential upside of 47.68% from the stock's previous close.

Several other equities analysts have also recently commented on SKIN. Wall Street Zen raised shares of Beauty Health from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Stifel Nicolaus boosted their target price on shares of Beauty Health from $3.00 to $4.00 and gave the company a "hold" rating in a research note on Friday, August 1st. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $2.92.

Beauty Health Stock Performance

Shares of SKIN stock opened at $2.37 on Friday. The company's fifty day simple moving average is $2.01 and its 200-day simple moving average is $1.64. Beauty Health has a 52 week low of $0.78 and a 52 week high of $2.69. The company has a current ratio of 5.15, a quick ratio of 4.15 and a debt-to-equity ratio of 4.91. The company has a market cap of $300.56 million, a PE ratio of -8.46 and a beta of 1.23.

Beauty Health (NASDAQ:SKIN - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.03 EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.09. Beauty Health had a negative net margin of 6.13% and a negative return on equity of 32.82%. The business had revenue of $78.20 million for the quarter, compared to the consensus estimate of $74.67 million. Beauty Health has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities research analysts anticipate that Beauty Health will post -0.25 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Soleus Capital Management L.P. acquired a new position in Beauty Health in the 2nd quarter valued at approximately $1,910,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Beauty Health by 40.8% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,570 shares of the company's stock worth $120,000 after buying an additional 18,128 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Beauty Health by 33.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 41,488 shares of the company's stock valued at $79,000 after purchasing an additional 10,410 shares during the period. Mirabella Financial Services LLP boosted its holdings in Beauty Health by 5.0% in the 2nd quarter. Mirabella Financial Services LLP now owns 12,861,549 shares of the company's stock valued at $24,566,000 after purchasing an additional 614,602 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of Beauty Health by 6.6% during the 2nd quarter. Invesco Ltd. now owns 98,427 shares of the company's stock worth $188,000 after acquiring an additional 6,059 shares during the period. Institutional investors and hedge funds own 93.26% of the company's stock.

Beauty Health Company Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.